Summarising the data, we can conclude that the addition of PRS impact gives additional information for more informed decisions regarding the management of breast cancer risk from MPVs, especially in the case of MPVs in the moderate-risk genes CHEK2 and ATM. This evidence concerns the gene ATM and breast carcinoma.